186 related articles for article (PubMed ID: 26770393)
1. Association between sodium iodide symporter and differentiated Thyroid cancer: a meta-analysis of 9 studies.
Zhang R; Wang H; Zhao J; Yao J; Shang H; Zhu H; Liao L; Dong J
Int J Clin Exp Med; 2015; 8(10):17986-94. PubMed ID: 26770393
[TBL] [Abstract][Full Text] [Related]
2. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
3. MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells.
Faria M; Domingues R; Bugalho MJ; Matos P; Silva AL
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831012
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
5. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
6. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
Cai X; Wang R; Tan J; Meng Z; Li N
Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
[TBL] [Abstract][Full Text] [Related]
8. Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study.
Lu YL; Chen ST; Ho TY; Chan WH; Wong RJ; Hsueh C; Lin SF
World J Clin Cases; 2021 Jan; 9(1):71-80. PubMed ID: 33511173
[TBL] [Abstract][Full Text] [Related]
9. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
10. Use of sodium iodide symporter expression in differentiated thyroid carcinomas.
Morari EC; Marcello MA; Guilhen AC; Cunha LL; Latuff P; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):247-54. PubMed ID: 21521301
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
Oh JM; Ahn BC
Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
[TBL] [Abstract][Full Text] [Related]
12. TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells.
Faria M; Domingues R; Paixão F; Bugalho MJ; Matos P; Silva AL
PLoS One; 2020; 15(2):e0228794. PubMed ID: 32049985
[TBL] [Abstract][Full Text] [Related]
13. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
14. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
15. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
16. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules.
Neumann S; Schuchardt K; Reske A; Reske A; Emmrich P; Paschke R
Thyroid; 2004 Feb; 14(2):99-111. PubMed ID: 15068624
[TBL] [Abstract][Full Text] [Related]
18. Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer.
Faria M; Domingues R; Bugalho MJ; Silva AL; Matos P
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771624
[TBL] [Abstract][Full Text] [Related]
19. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
